State of the Art Management in Relapsed/Refractory CLL

Download these slides from our ASCO 2021 live satellite webinar on CLL to review the most current clinical data on treating patients with relapsed/refractory CLL.
Anthony Mato, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 17.81 MB
Released: June 8, 2021

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC.
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
education@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Supported by educational grants from
AbbVie
AstraZeneca
BeiGene, Ltd.
Lilly
Pharmacyclics LLC and Janssen

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Key clinical insights from Drs Suzanne Lentzsch and Saad Usmani on individualizing care for patients with MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Released: June 17, 2021

Downloadable on the evolving role of PI3K inhibitors for patients with relapsed and refractory follicular lymphoma, from Clinical Care Options (CCO)

John M. Burke, MD Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue